Biomerica, Inc. (BMRA): Price and Financial Metrics

Biomerica, Inc. (BMRA): $0.58

0.02 (+3.04%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

BMRA Price/Volume Stats

Current price $0.58 52-week high $2.13
Prev. close $0.56 52-week low $0.50
Day low $0.56 Volume 22,606
Day high $0.58 Avg. volume 168,487
50-day MA $0.65 Dividend yield N/A
200-day MA $0.91 Market Cap 9.71M

BMRA Stock Price Chart Interactive Chart >


Biomerica, Inc. (BMRA) Company Bio


Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.


BMRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRA Latest Social Stream


Loading social stream, please wait...

View Full BMRA Social Stream

Latest BMRA News From Around the Web

Below are the latest news stories about BIOMERICA INC that investors may wish to consider to help them evaluate BMRA as an investment opportunity.

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!

William White on InvestorPlace | December 19, 2023

Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population

Over 80% of gastric cancers are attributed to H. pylori bacterial infection Gastric cancer is the third most common cause of cancer related death in the world H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELI

Yahoo | December 18, 2023

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings. About Biomerica (NASDAQ:

Yahoo | November 10, 2023

Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups

Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National Accounts hired along with first set of regional sales representatives IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using

Yahoo | November 8, 2023

Read More 'BMRA' Stories Here

BMRA Price Returns

1-mo -4.76%
3-mo -45.28%
6-mo -41.41%
1-year -65.06%
3-year -85.71%
5-year -75.27%
YTD -53.60%
2023 -62.69%
2022 -13.88%
2021 -21.89%
2020 64.68%
2019 77.88%

Continue Researching BMRA

Here are a few links from around the web to help you further your research on Biomerica Inc's stock as an investment opportunity:

Biomerica Inc (BMRA) Stock Price | Nasdaq
Biomerica Inc (BMRA) Stock Quote, History and News - Yahoo Finance
Biomerica Inc (BMRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!